The Most Effective Drug Is the One She Should Not Take: Choosing a First Antiseizure Medicine for a 24-Year-Old Woman With Newly Diagnosed Generalized Epilepsy
[Student Name]
University of Phoenix
NRP/507: Advanced Pharmacology
Week 6 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper. In practice, neurology would confirm the diagnosis and share the initial treatment decision.
Ms. L., a 24-year-old veterinary assistant, had two generalized tonic-clonic seizures four months apart. Her electroencephalogram showed generalized spike-and-wave discharges, and her MRI was normal. Her neurologist diagnosed idiopathic generalized epilepsy and asked me, as her primary care nurse practitioner, to help start and monitor treatment because the neurology clinic's next opening is two months away. She takes a combined oral contraceptive containing ethinyl estradiol and hopes to have children in three or four years. This paper explains how we chose her first antiseizure medicine.
The Evidence on Efficacy
For generalized epilepsy, valproate has long been considered the most effective drug. The SANAD II trial randomly assigned 520 patients with newly diagnosed generalized or unclassifiable epilepsy to valproate or levetiracetam. Levetiracetam did not meet the criteria for noninferiority for time to 12-month remission, and the per-protocol analysis favored valproate; the authors concluded that their results should inform discussions with girls and women of childbearing potential about the benefits and harms of avoiding valproate (Marson et al., 2021). The American Academy of Neurology guideline on newer drugs for new-onset epilepsy found that data were lacking on the efficacy of second-generation drugs in new-onset generalized tonic-clonic seizures (Kanner et al., 2018).
The Evidence on Harm
The EURAP registry followed 7,355 pregnancies exposed to one of eight antiseizure drugs. Major congenital malformations occurred in 10.3% of pregnancies exposed to valproate, compared with 2.9% for lamotrigine and 2.8% for levetiracetam, and risk rose with dose for valproate, lamotrigine, carbamazepine and phenobarbital (Tomson et al., 2018). The authors noted that risks with lamotrigine, levetiracetam and oxcarbazepine were within the range reported for children not exposed to these drugs.
For Ms. L., the drug that best controls seizures is also the drug most likely to harm a child she plans to have, and the choice has to be made now, years before the pregnancy.
Why Not Valproate
Valproate would be reasonable for a man or for a woman who could not become pregnant. For Ms. L., its tenfold-plus risk of major malformations compared with the general population, and additional risks to cognitive development described elsewhere in the literature, outweigh its advantage in seizure control, especially while other drugs remain untried. Starting valproate now and switching before pregnancy would expose her to a switch at a vulnerable time and to any unplanned pregnancy in between.
Levetiracetam or Lamotrigine
Both carry low malformation risks in the registry (Tomson et al., 2018). The choice between them turns on her other medications and her situation.
Lamotrigine interacts with her contraceptive. Ethinyl estradiol increases lamotrigine clearance, which can lower levels substantially and lead to breakthrough seizures, and levels rise again during the pill-free week. Lamotrigine also requires a slow titration over six weeks or more to reduce the risk of serious rash, leaving her less protected in the meantime.
Levetiracetam does not interact meaningfully with hormonal contraceptives, can be started at a therapeutic dose and needs no titration for rash. Its main drawback is behavioral: irritability, low mood and, rarely, more serious psychiatric effects. Ms. L. has no history of depression.
The Decision
After discussion with her neurologist and with Ms. L., we start levetiracetam 500 mg by mouth twice daily, with a plan to increase to 1,000 mg twice daily after two weeks if needed. The dose is adjusted for kidney function, which is normal for her.
Mechanism
Levetiracetam binds synaptic vesicle protein 2A, which modulates neurotransmitter release; the exact way this reduces seizures is not fully understood. It is renally cleared, has few drug interactions and has predictable pharmacokinetics.
Contraception
Because levetiracetam does not reduce the effectiveness of her pill, she can continue it. I explain that if another drug is ever added, such as carbamazepine or oxcarbazepine, her contraceptive may become less reliable, and she should always tell any prescriber that she takes an antiseizure drug.
Dosing Details
Levetiracetam comes as tablets and an oral solution and is absorbed almost completely, with or without food. Steady state is reached within about two days, so the effect of a dose change can be judged quickly. With renal elimination as its main route, the dose would come down if her kidney function ever declined, and levels during pregnancy tend to fall as kidney clearance rises, which her neurologist will watch when the time comes.
What If Levetiracetam Fails?
If seizures continue at a full dose or she cannot tolerate the mood effects, lamotrigine would be the next choice, started slowly and with the contraceptive interaction managed either by adjusting the dose or by switching her to a progestin-only or nonhormonal method in consultation with her gynecologic provider. Valproate would be reconsidered only after other options had failed, and only with full counseling, highly effective contraception and her informed agreement, documented in writing.
Folic Acid and Pregnancy Planning
I recommend folic acid daily now, since many pregnancies are unplanned. When she plans to conceive, she should meet with her neurologist first to confirm the lowest effective dose and consider a level to guide monitoring during pregnancy.
Monitoring
I will see her in two weeks and at three months, asking about seizures, mood, irritability and sleep. She will keep a seizure diary. I will screen for depression at each visit and ask her partner, with her permission, to tell us about any change in mood. If she has another seizure, we will review adherence and consider increasing the dose before switching.
Safety and Daily Life
Seizure safety matters while treatment takes effect. Our state requires a seizure-free period before driving, and I explain the law and document the conversation. She should avoid bathing alone, working at heights and handling sedating veterinary drugs while seizures are uncontrolled, and she should limit alcohol and protect her sleep, since sleep loss is a common trigger in generalized epilepsy.
Coordinating Care
I send a summary of our discussion and the plan to her neurologist the same day, including the reasoning about valproate and contraception, so the specialist visit in two months can build on it. Ms. L. receives a copy through the patient portal. She also receives a letter for her employer about her diagnosis and any temporary restrictions, written only with her consent and limited to what the employer needs to know.
Teaching Her Family
Her roommate and partner will learn seizure first aid: time the seizure, turn her on her side, keep her from injury, put nothing in her mouth and call 911 if a seizure lasts more than five minutes or she does not wake up between seizures.
Conclusion
SANAD II showed that valproate controls generalized seizures better than levetiracetam, but the EURAP registry showed a malformation rate more than three times higher than with levetiracetam or lamotrigine. For a woman planning children, that tradeoff favors a safer drug. Between the safer options, levetiracetam's lack of interaction with her contraceptive and its simple start made it the better first choice, with mood monitoring and pregnancy planning built into the plan.
References
Kanner, A. M., Ashman, E., Gloss, D., Harden, C., Bourgeois, B., Bautista, J. F., Abou-Khalil, B., Burakgazi-Dalkilic, E., Llanas Park, E., Stern, J., Hirtz, D., Nespeca, M., Gidal, B., Faught, E., & French, J. (2018). Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy. Neurology, 91(2), 74-81. https://doi.org/10.1212/WNL.0000000000005755
Marson, A., Burnside, G., Appleton, R., Smith, D., Leach, J. P., Sills, G., Tudur-Smith, C., Plumpton, C., Hughes, D. A., Williamson, P., Baker, G. A., Balabanova, S., Taylor, C., Brown, R., Hindley, D., Howell, S., Maguire, M., Mohanraj, R., Smith, P. E., . . . Jauhari, P. (2021). The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: An open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. The Lancet, 397(10282), 1375-1386. https://doi.org/10.1016/S0140-6736(21)00246-4
Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Perucca, E., Sabers, A., Thomas, S. V., Vajda, F., Faravelli, F., Pantaleoni, C., Robert-Gnansia, E., Cabral-Lim, L., Čebular, B., De Marinis, A., Kälviäinen, R., Khomeriki, K., Kiteva-Trencevska, G., Kochen, S., . . . Zarifi-Oskoie, M. (2018). Comparative risk of major congenital malformations with eight different antiepileptic drugs: A prospective cohort study of the EURAP registry. The Lancet Neurology, 17(6), 530-538. https://doi.org/10.1016/S1474-4422(18)30107-8
How this NRP 507 Week 6 example is structured
The NRP/507 Week 6 work usually asks for a neurological drug therapy decision with its evidence, dosing and monitoring. This paper puts efficacy and harm side by side, since the drug that controls seizures best carries the greatest risk to a future pregnancy, and makes the choice with the patient's plans and her other medications in view. Students search this week as NRP 507 Week 6, NRP507 Wk 6 or NRP/507 Wk 6; all three are the same assignment.
NRP/507 Week 6 questions, answered
What does NRP/507 Week 6 usually ask for?
Many sections present a neurological case, such as seizures, migraine or neuropathic pain, and ask for drug selection with evidence, mechanism, dosing, interactions and monitoring.
Why is valproate avoided in women who could become pregnant?
It carries the highest risk of major congenital malformations among common antiseizure drugs, as well as risks to neurodevelopment, so it is generally avoided unless other drugs have failed.
Does estrogen affect lamotrigine?
Yes. Estrogen-containing contraceptives increase lamotrigine clearance and can lower its levels substantially, so doses may need adjustment when these contraceptives are started or stopped.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.